華潤三九(000999.SZ):擬以29.02億元收購昆藥集團28%的股份
格隆匯5月8日丨華潤三九(000999.SZ)公佈,公司擬以支付現金的方式向華立醫藥購買其所持有的昆藥集團208,976,160股股份(佔昆藥集團已發行股份總數的27.56%),並向華立集團購買其所持有的昆藥集團3,335,456股股份(佔昆藥集團已發行股份總數的0.44%)。此次交易標的股份價格擬定為29.02億元,對應昆藥集團每股轉讓價格為人民幣13.67元。
此次交易完成後,上市公司將持有昆藥集團212,311,616股股份(佔昆藥集團已發行股份總數的28%),昆藥集團將成為華潤三九的控股子公司。
公司從事醫藥產品的研發、生產、銷售及相關健康服務,主營核心業務定位於CHC健康消費品和處方藥領域。CHC健康消費品業務覆蓋了感冒、皮膚、胃腸、止咳、骨科、兒科等近10個品類,其核心產品在感冒、胃腸、皮膚、兒科、維礦、止咳和骨科用藥佔據了較高的市場份額;處方藥業務則聚焦消化、骨科、心腦重症、腫瘤核心領域,位居國內市場前列。此次重組符合華潤三九戰略,可在華潤三九良好的品牌運作能力基礎上,探索將“昆中藥1381”、“昆中藥”打造為精品國藥品牌,以此承載更多具有歷史沉澱的產品,並有利於推動以三七為代表的中醫藥產業鏈高質量發展,打造三七產業鏈龍頭企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.